These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1538914)

  • 1. [Oncogenes and pharmacological approaches to cancer therapy].
    Tocque B
    Pathol Biol (Paris); 1992 Nov; 39(9):869-70. PubMed ID: 1538914
    [No Abstract]   [Full Text] [Related]  

  • 2. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides.
    Calabretta B; Skorski T; Zon G
    Semin Cancer Biol; 1992 Dec; 3(6):391-8. PubMed ID: 1286160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Bcl-2 family in cancer therapy.
    Papadopoulos K
    Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense therapy in cancer.
    Pawlak W; Zolnierek J; Sarosiek T; Szczylik C
    Cancer Treat Rev; 2000 Oct; 26(5):333-50. PubMed ID: 11006135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches in cancer pharmacology: drug design and development. Report of a European School of Oncology Task Force.
    Eur J Cancer; 1992; 28A(6-7):1190-200. PubMed ID: 1627393
    [No Abstract]   [Full Text] [Related]  

  • 10. Custom cancer therapies: safe and effective treatments for most or all cancers.
    Summerton JE
    Ann N Y Acad Sci; 2003 Dec; 1002():189-96. PubMed ID: 14751835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer therapy finds a solid target.
    Secko D
    CMAJ; 2005 Aug; 173(3):246. PubMed ID: 16076816
    [No Abstract]   [Full Text] [Related]  

  • 13. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
    Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
    [No Abstract]   [Full Text] [Related]  

  • 14. Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics.
    McGraw K; McKay R; Miraglia L; Boggs RT; Pribble JP; Muller M; Geiger T; Fabbro D; Dean NM
    Anticancer Drug Des; 1997 Jul; 12(5):315-26. PubMed ID: 9236849
    [No Abstract]   [Full Text] [Related]  

  • 15. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G 3139. Augmerosen, Bcl-2 antisense oligonucleotide--Genta, GC 3139, Genasense.
    Drugs R D; 2002; 3(1):44-9. PubMed ID: 11881530
    [No Abstract]   [Full Text] [Related]  

  • 18. Advancements of antisense oligonucleotides in treatment of breast cancer.
    Yang SP; Song ST; Song HF
    Acta Pharmacol Sin; 2003 Apr; 24(4):289-95. PubMed ID: 12676065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A novel paradigm and new targets in cancer therapy].
    Novik AA; Kamilova TA; Tsygan VN
    Vopr Onkol; 2003; 49(6):695-704. PubMed ID: 14976912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.